Back

Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study

18 May 2025 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Beating the odds: advances in cardiac amyloidosis treatment Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Laura Obici

I.R.C.C.S. San Matteo Polyclinic, Pavia (Italy)

6 More presentations in this session

Presentation thumbnail
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
Assistant Professor K. Alexander (Palo Alto, US)
Abstract Slides Video
Presentation thumbnail
Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis
Mr M. Mueller (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Beating the odds: advances in cardiac amyloidosis treatment

The Event

Event poster

Heart Failure 2025

18 May 2025 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
thumbnail
Congress Presentation
ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources